1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Selecta/Sobi Gout Drug Numerically, Not Significantly, Beat Krystexxa

SEL-212 Bested Horizon’s Drug But A New Standard Is Emerging

 
• By Mandy Jackson

Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.

On a purple background a stethoscope with yellow list with text GOUT
Selecta and Sobi already have started Phase III trials for SEL-212 • Source: Shutterstock

Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Sobi) touted a successful conclusion of the Phase IIb COMPARE clinical trial, which showed that SEL-212 performed numerically better than Horizon Therapeutics plc’s Krystexxa (pegloticase) for chronic refractory gout. However, SEL-212 did not measure up to a new emerging standard of care for this patient population, so the drug candidate’s commercial prospects may be reduced.

The COMPARE trial did not meet its primary endpoint, which compared the percentage of patients treated with SEL-212 versus the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

More from R&D

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.